Even among melanoma patients with the highest response rate to ICB, more than 60–70% of patients do not respond positively to anti-PD-1 antibody therapy; 20–30% of these patients eventually show tumor recurrence and progression [125, 126]. This evidence concerns the gene PDCD1 and neoplasm.